Galderma Group AG: Rosacea trials

The registry lists 29 Rosacea studies with Galderma Group AG as lead sponsor. 0 are open to participants now and 22 have results posted.

Phase 2 5Phase 3 11Phase 4 9No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Oracea Soolantra Association in Participants With Severe RosaceaCompletedNCT03075891Phase 4Results posted
• Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)CompletedNCT02637232Results posted
• MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.CompletedNCT02616250Phase 4Results posted
• Effect of CD07805/47 Gel in Rosacea FlushingCompletedNCT02300129Phase 2Results posted
• Mirvaso in Use StudyCompletedNCT02249065Phase 4Results posted
• Patient-Reported Outcome Of Facial Erythema (PROOF)CompletedNCT01885000Phase 3Results posted
• Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on OraceaCompletedNCT01872715Phase 4Results posted
• Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of RosaceaCompletedNCT01789775Phase 3Results posted
• Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of RosaceaCompletedNCT01659853Phase 3Results posted
• Phase 3 Papulopustular Rosacea StudyCompletedNCT01494467Phase 3Results posted
• CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) StudyCompletedNCT01493947Phase 3Results posted
• Phase 3 Papulopustular Rosacea StudyCompletedNCT01493687Phase 3Results posted
• Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs PlaceboCompletedNCT01426269Phase 4Results posted
• Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With RosaceaCompletedNCT01355471Phase 3Results posted
• Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With RosaceaCompletedNCT01355458Phase 3Results posted
• Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With RosaceaCompletedNCT01318733Phase 3Results posted
• Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs PlaceboCompletedNCT01308619Phase 4Results posted
• Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With RosaceaCompletedNCT01174030Phase 2Results posted
• Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic RosaceaCompletedNCT00989014Phase 2Results posted
• ORCA - Oracea® for Rosacea: A Community-based AssessmentCompletedNCT00892281Phase 4Results posted
• Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%CompletedNCT00697541Phase 2Results posted
• Treatment of Patients With Blepharitis and Facial RosaceaCompletedNCT00560703Phase 2Results posted
• Rosacea Prevalence in General Population - Pilot StudyCompletedNCT02292836
• Assessment of the Rosacea Prevalence in the General PopulationCompletedNCT02292797
• An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%CompletedNCT00668655
• Safety and Efficacy Study to Compare Two Rosacea Treatment RegimensCompletedNCT00495313Phase 4
• Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single ApplicationCompletedNCT00436527Phase 4
• A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of RosaceaCompletedNCT00126399Phase 3
• Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne RosaceaCompletedNCT00041977Phase 3